Effectiveness of omega-3 polysaturated fatty acids (fish oil) supplementation for treating hypertriglyceridemia in children and adolescents

Clinical Pediatrics

Volumn 53, Issue 7, 2014, Pages 645-651

  Chahal, Nita ^a   Manlhiot, Cedric ^a   Wong, Helen ^a   McCrindle, Brian W ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

dyslipidemia; fish oil; pediatrics; treatment

Indexed keywords

ANTILIPEMIC AGENT; BILE ACID SEQUESTRANT; EZETIMIBE; FENOFIBRATE; FISH OIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRIACYLGLYCEROL; OMEGA 3 FATTY ACID;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; CARDIOLOGIST; CHILD; CHILDHOOD DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET SUPPLEMENTATION; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; NUTRITION; PHYSICAL ACTIVITY; RETROSPECTIVE STUDY; THERAPY EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; DIETARY SUPPLEMENT; TREATMENT OUTCOME;

ADOLESCENT; CHILD; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; FEMALE; FISH OILS; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84904903818     PISSN: 00099228     EISSN: 19382707     Source Type: Journal    
DOI: 10.1177/0009922814527503     Document Type: Article

References (42)

1. Manlhiot C, Larsson P, Gurofsky RC, et al. Spectrum and management of hypertriglyceridemia among children in clinical practice. Pediatrics. 2009 ; 123: 458-465
2. Yuan G, Al-Shali KZ, Hegele RA.. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ. 2007 ; 176: 1113-1120
3. Assmann G, Cullen P, Schulte H.. The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J. 1998 ; 19: A2 - A11
4. Berenson GS, Srinivasan SR, Bao W, Newman WP, Tracy RE, Wattigney WA.. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 1998 ; 338: 1650-1656
5. Criqui MH, Heiss G, Cohn R, et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med. 1993 ; 328: 1220-1225
6. Cullen P.. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol. 2000 ; 86: 943-949
7. Hokanson JE, Austin MA.. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996 ; 3: 213-219
8. Hopkins PN, Wu LL, Hunt SC, Brinton EA.. Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease. J Am Coll Cardiol. 2005 ; 45: 1003-1012
9. McCrindle BW, Manlhiot C.. Elevated atherogenic lipoproteins in childhood: risk, prevention, and treatment. J Clin Lipidol. 2008 ; 2: 138-146
10. McCrindle BW Pediatic Obesity: Etiology, Pathogenesis, and Treatment. Freemark M, ed. Totowa, NJ: Humana Press ; 2010: 175-200.
11. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011 ; 123: 2292-2333
12. Klop B, Wouter Jukema J, Rabelink TJ, Castro Cabezas M.. A physician's guide for the management of hypertriglyceridemia: the etiology of hypertriglyceridemia determines treatment strategy. Panminerva Med. 2012 ; 54: 91-103
13. McCrindle BW, Urbina EM, Dennison BA, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation. 2007 ; 115: 1948-1967
14. Balk E, Chung M, Lichtenstein A, et al. Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovascular disease. Evid Rep Technol Assess (Summ). 2004: 1-6
15. Jonkers IJ, Smelt AH, Princen HM, et al. Fish oil increases bile acid synthesis in male patients with hypertriglyceridemia. J Nutr. 2006 ; 136: 987-991
16. Kris-Etherton PM, Taylor DS, Yu-Poth S, et al. Polyunsaturated fatty acids in the food chain in the United States. Am J Clin Nutr. 2000 ; 71: 179S - 188S
17. Division of Nutrition, Physical Activity, and Obesity, National Center for Chronic Disease Prevention and Health Promotion. Growth Chart 2012. http://www.cdc.gov/growthcharts/cdc-charts.htm. Accessed February 28, 2014.
18. Khoury M, Manlhiot C, Dobbin S, et al. Role of waist measures in characterizing the lipid and blood pressure assessment of adolescents classified by body mass index. Arch Pediatr Adolesc Med. 2012 ; 166: 719-724
19. Thavendiranathan P, Jones E, Han RK, et al. Association between physical activity, adiposity, and lipid abnormalities in children with familial hyperlipidemia. Eur J Cardiovasc Prev Rehabil. 2007 ; 14: 59-64
20. Katamay SW, Esslinger KA, Vigneault M, et al. Eating well with Canada's Food Guide (2007): development of the food intake pattern. Nutr Rev. 2007 ; 65: 155-166
21. Gidding SS, Dennison BA, Birch LL, et al. Dietary recommendations for children and adolescents: a guide for practitioners. Pediatrics. 2006 ; 117: 544-559
22. Hayman LL, Himmelfarb CD.. Cardiovascular health promotion and risk reduction in children and adolescents: the new integrated guidelines. J Cardiovasc Nurs. 2012 ; 27: 197-200
23. Arai H, Ishibashi S, Bujo H, et al. Management of type IIb dyslipidemia. J Atheroscler Thromb. 2012 ; 19: 105-114
24. Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG.. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care. 2002 ; 25: 1198-1202
25. Harris WS, Ginsberg HN, Arunakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk. 1997 ; 4: 385-391
26. Pownall HJ, Brauchi D, Kilinc C, et al. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis. 1999 ; 143: 285-297
27. Harris WS.. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr. 1997 ; 65: 1645S - 1654S
28. Pejic RN, Lee DT.. Hypertriglyceridemia. J Am Board Fam Med. 2006 ; 19: 310-316
29. Harris WS.. Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J Lipid Res. 1989 ; 30: 785-807
30. Harris WS, Bulchandani D.. Why do omega-3 fatty acids lower serum triglycerides?. Curr Opin Lipidol. 2006 ; 17: 387-393
31. Ford ES.. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005 ; 28: 1769-1778
32. Klein BE, Klein R, Lee KE.. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care. 2002 ; 25: 1790-1794
33. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003 ; 108: 414-419
34. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F.. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation. 1998 ; 97: 1029-1036
35. Yarnell JW, Patterson CC, Sweetnam PM, et al. Do total and high density lipoprotein cholesterol and triglycerides act independently in the prediction of ischemic heart disease? Ten-year follow-up of Caerphilly and Speedwell Cohorts. Arterioscler Thromb Vasc Biol. 2001 ; 21: 1340-1345
36. Brousseau ME, O'Connor JJ, Ordovas JM, et al. Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial. Arterioscler Thromb Vasc Biol. 2002 ; 22: 1148-1154
37. Linsel-Nitschke P, Tall AR.. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov. 2005 ; 4: 193-205
38. Khoury M, Manlhiot C, Mccrindle BW.. Role of the waist-to-height ratio in the cardiometabolic risk assessment of children classified by body mass index. J Am Coll Cardiol. 2013 ; 62: 742-751
39. Hegele RA.. Monogenic dyslipidemias: window on determinants of plasma lipoprotein metabolism. Am J Hum Genet. 2001 ; 69: 1161-1177
40. Harris WS, Connor WE, Alam N, Illingworth DR.. Reduction of postprandial triglyceridemia in humans by dietary n-3 fatty acids. J Lipid Res. 1988 ; 29: 1451-1460
41. Sanders TA, Oakley FR, Miller GJ, Mitropoulos KA, Crook D, Oliver MF.. Influence of n-6 versus n-3 polyunsaturated fatty acids in diets low in saturated fatty acids on plasma lipoproteins and hemostatic factors. Arterioscler Thromb Vasc Biol. 1997 ; 17: 3449-3460
42. Roche HM, Gibney MJ.. Postprandial triacylglycerolaemia: the effect of low-fat dietary treatment with and without fish oil supplementation. Eur J Clin Nutr. 1996 ; 50: 617-624